Children as young as 9 months can now be immunized for the prevention of meningococcal disease.
Children as young as 9 months now can be immunized for the prevention of invasive meningococcal disease, according to FDA.
Menactra (Sanofi Pasteur; Swiftwater, Pennsylvania) tetravalent conjugate vaccine was first approved in 2005 to protect people aged 2 through 55 years against meningitis caused by Neisseria meningitidis serogroups A, C, Y and W-135. The bacteria invade the bloodstream and the meninges that surround the brain and spinal cord and can cause neurologic problems, coma, and even death.
Between 10% and 15% of patients who develop meningococcal disease die from the infection, and another 10% to 20% develop complications such as brain damage or loss of limbs and hearing.
FDA granted approval for Menactra in this age group after reviewing 4 clinical studies that evaluated the safety of Menactra for children as young as 9 months.
The most common adverse effects reported in children who received the Menactra vaccine were comparable to a control group that received other childhood vaccinations: tenderness at the injection site, fever, and general irritability. Serious adverse events recorded through 6-month follow-up occurred in less than 3% of the children.
The benefits of concurrent fetal and maternal heart rate monitoring
April 17th 2024A recent study revealed that employing maternal heart rate monitoring alongside fetal heart rate monitoring during labor significantly decreases the incidence of neonatal encephalopathy and severe neonatal acidemia.